Dr John Dillon NHS Tayside Brian Stephens NHS Tayside Jan Tait NHS Tayside Daniel Kelly CAIR Scotland Ingrid Hainey CAIR Scotland Mike Burns CAIR Scotland.

Slides:



Advertisements
Similar presentations
Effective treatment. Changing lives Needs Assessment Tools Past, Present and Future Data and methods available for carrying out needs assessment 25 th.
Advertisements

Meeting need and improving coverage workshop. Meeting need: calculating and improving coverage.
Needle exchange: an NTA perspective 1 July 2009 Hugo Luck.
Injecting and BBVs – NDTMS and prevalence data Current prevalence data for injecting among opiate/crack users (2010/11) shows continuation of a steady.
List inflation Sandy Fitzpatrick Head of Information and Registration Unit Business Services Organisation.
Turning the tide: Not without prisons! Promoting comprehensive national HIV responses.
Improving the wider social determinants of Health in Sunderland through Informal Care in Sunderland By Nicola Turnbull WHO Healthy City Support.
Supporting people who use drugs & providers: hep C info & care Magdalena Harris London School of Hygiene and Tropical Medicine
Dundee Dementia Information Service Maureen Hood Library and Information Officer.
Quality Education for a Healthier Scotland Designing Career Plans – Sharing views from the health sector Career and Development Framework for Nurses, Midwives.
HIV and Hepatitis B or C co-infection Preliminary results of survey.
Hepatitis C prevention among people who inject drugs: reducing transmission in PWID by scaling up HCV treatment, OST and needle exchange services Matt.
Scotland’s Hepatitis C Action Plan, a patient approach?
Hepatitis C Action Plan Prevention Working Group Findings and recommendations Norah Palmateer Health Protection Scotland Greater Glasgow & Clyde MCN June.
The LJWG 2014 conference is funded through educational grants from AbbVie Ltd, Gilead Sciences Ltd and MSD Ltd and sponsored by Bristol-Myers Squibb. None.
DAIWA Anglo Japanese Research Exchange Visit 14 November 2005.
Needs Assessment of Hepatitis C Testing, Treatment and Support Services: Survey of Laboratories in Scotland Undertaking Hepatitis C Testing.
© Cancer Research UK 2011 Registered charity in England and Wales ( ) and Scotland (SC041666) Cervical Cancer - UK December 2011 For more information.
© Cancer Research UK 2012 Registered charity in England and Wales ( ) and Scotland (SC041666)
The UK Drugs Situation: Data, information and uses Charlotte Davies, UK Focal Point Project Manager 1.
Estimation of the Prevalence of Problem Drug Use in Lithuania Dr Gordon Hay Centre for Drug Misuse Research University of Glasgow, United Kingdom.
Hepatitis C- Global and National Perspective Dr Allister Grant Consultant Hepatologist University Hospitals Leicester NHS Trust.
HIV, drugs and prisons in Russia Anya Sarang. Russia estimated 2 mln IDUs 1,5 estimated HIV cases HIV prevalence in IDUs reaches 75% in some cities HCV.
Hepatitis C Testing in the Muslim Community Hasnain Jafferbhoy Grampian Hepatitis Stakeholder Conference 16 th June 2011.
Naomi Salisbury – June 2009 ‘Much More Than a Label’ Consultation with People who have Experience of Personality Disorder in Lothian.
Dundee Partnership Community Conference 17 th September 2011 What are we trying to achieve? The national picture Dr Brian Kidd – NHS Tayside.
To Increase Investment in Syringe Exchange in the U.S. would be Cost-saving. Results from modeling hypothetical syringe coverage levels INTL AIDS CONF.
Drug Use and Hepatitis C Are we mindful of the gaps? Dave Liddell, SDF.
Dr Gilles Raguin, on behalf of ESTHER Senegal, IAS, 2012 HIV Prevention, treatment and care for IDUs in Senegal: An innovative ESTHER partnership.
The Power of Innovation and Collaboration: Securing the Future of General Practice Why GPs need to do something different Dr Mike Bewick NHS England -
Dr Ashley Brown Consultant Hepatologist, St. Mary’s and Hammersmith Hospitals, London and Honorary Senior Lecturer, Imperial College London The Updated.
Dr Neil Douglas GP Clinical Lead Child Health.  In the UK responsible for the largest number of disability adjusted life years lost of any single childhood.
An online solution for the supply of mobility products.
1 Needle Exchange Provision in Scotland Selected results from the National Needle Exchange Survey Dawn Griesbach Griesbach & Associates 28 February 2007.
Pennsylvania: The State of HCV 2015
WHY THE CONCERN ABOUT ALCOHOL? AND WHAT DOES IT HAVE TO DO WITH GENERAL PRACTICE? Peter Rice, Consultant Psychiatrist, NHS Tayside.
Senior Drug Users: Scotland April Shaw & Austin Smith November 2009.
Decline in incidence of HIV and Hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? 1. Julius Center, University.
Harm Reduction Team Maureen Woods Team Leader. Service Delivery Aims Develop harm reduction initiatives in partnership with other agencies to reduce the.
DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration OFFICE OF APPLIED STUDIES Treatment Episode Data Set.
Hepatitis C Needs Assessment: Contributions from the National HCV Diagnosis and Local Clinical Databases.
 Financial framework  Core outcomes  Community Safety  2013/14.
#LJWG2015 HEPATITIS C IN PEOPLE WHO USE DRUGS Improving Care for Hepatitis C: A Framework Approach LONDON 2015.
How big is the problem locally? Dr Stephen Willott GP and Clinical Lead for Drug Misuse & Alcohol NHS Nottingham City …& what are we doing about it?
Almost everything you ever wanted to know about Integrated Addiction Services but were too afraid to ask Christine Laverty Head of Addiction Services North.
Alcohol Drugs and Hepatitis C, Brewing up a perfect storm COSLA Haymarket, Edinburgh 24 June 2015 Epidemiological overview Professor David Goldberg, Health.
From evidence to commitment to action: implementing HIV prevention measures in prisons in Ukraine XVI International AIDS Conference Toronto, 15 August.
South West Hepatitis C Needs Assessment Dr Maya Gobin Health Protection Services (South West)
Developing role of community pharmacy in responding to the needs of people with drug problems David Thomson Lead Pharmacist Community Pharmacy Development.
Where do we go from here? Dr. Nicola D. Rowan Dr. Nicola D. Rowan UK Hepatitis C Resource Centre “Scotland”
Acknowledgments Lifescan Inverness Introduction  Diabetes Mellitus is the 5 th most common cause of death in the world  Life expectancy reduced on average.
Break The Cycle (Preventing initiation into injecting) Integrating brief interventions into practice. Simon Pringle Drugs Action Aberdeen
Hepatitis C and Sexual & Reproductive Health Graham Mackintosh, Training & Capacity Officer Lesley Bon, Patient Involvement Officer.
Healthcare Genetics in the NHS Landscape 1 st Gengage Network Conference June 2009 Dr Mike Winter Medical Director National Services Division.
Where Are We on the Path to Elimination of Chronic Hepatitis C?
Patient Activism Charles Gore.
Needle and syringe exchange and working with injecting drug users
Hepatitis B and C management pathways in prison:
Coverage of HIV and HCV prevention interventions for people who inject drugs Dr Sarah Larney, Senior Research Fellow.
More Than Treatment.
HCV Screening.
Edward Mbizo Sibanda, (MSc) Right to Care
China 2010 UNGASS Country Progress Report
The cost-effectiveness of needle and syringe provision in preventing transmission of Hepatitis C Virus in people who inject drugs in the UK Zoë Ward1,
ENDING THE EPIDEMICS: A FOCUS ON PEOPLE WHO INJECT DRUGS
CHAPTER 10 Hepatitis on Dialysis
Blood borne viral hepatitis action in Wales
Communicable Disease Surveillance Centre, London
Hepatitis C case-finding – An opportunity for community pharmacy
Share your thoughts on this presentation with #IAS2019
Presentation transcript:

Dr John Dillon NHS Tayside Brian Stephens NHS Tayside Jan Tait NHS Tayside Daniel Kelly CAIR Scotland Ingrid Hainey CAIR Scotland Mike Burns CAIR Scotland Ann Eriksen NHS Tayside Executive Leads

0.5% Average UK Prevalence of HCV 0.5% 1% Tayside Prevalence of HCV 1% 20% Prevalence in Injecting Drug Users in Tayside 20% 2285 Estimated Positive Population in Tayside 2285 The partnership between CAIR Scotland and NHS Tayside, starting in 2009, contributed to an almost 200% increase in confirmed new HCV diagnosis in Tayside Resulted in funding to carry out an Eradication Study with a view to eradicating Hepatitis C.

65% Average DNA Rate 65%

930 DBST Carried out in the CAIR Scotland Needle Exchange Centre, City of Dundee % Returned for Results 89% 80% From our most socially deprived areas 80% 70% Currently in Drug Treatment 70%

ʺ ʺ